Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Panel of Alcon Directors Rejects Novartis Bid

By Pharmaceutical Processing | January 20, 2010

GENEVA (AP) — A panel of directors at eye-care company Alcon Inc. on Wednesday rejected as “grossly inadequate” a $39 billion takeover bid by Swiss pharmaceutical giant Novartis AG. The rejection by the committee — made up of three independent board members — follows a similar response from minority shareholders to Novartis’ Jan. 4 announcement that it plans to pay $38.5 billion for the 77 percent stake in Alcon it does not already own. “The committee has determined that the Novartis merger proposal is grossly inadequate,” the panel said in a letter to Daniel Vasella, chairman and CEO of Novartis. It said Novartis’ analysis underlying its merger proposal was “fundamentally flawed” and “not in the best interests of Alcon and its minority shareholders.” Alcon set up the committee to evaluate the proposed merger based on financial and legal counsel. The deal also requires regulatory approval. Novartis said it was buying Nestle SA’s 52 percent stake for $28 billion in cash before carrying out a merger with Alcon that would give it control of the remaining 23 percent held by minority shareholders. The minority shareholders then filed a class-action lawsuit in U.S. District Court in New York to prevent Novartis from completing the takeover. The Basel-based drug maker had already purchased 25 percent of Alcon from Nestle in April 2008 for $11 billion, with the option of buying the food and drinks company’s remaining stake at a later date.

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE